Best of ASCO China breast cancer articles

Schematic diagram of breast cancer

· Current on T1 ~ 2N0 ~ 1 issues (< 5 cm tumor, lymph node number is 1 ~ 3) breast cancer patients treated with radical mastectomy for radiotherapy is still disputed;

· Bevacizumab combined with Capecitabine, anthracyclines/taxol class chemotherapy first-line treatment of metastatic breast cancer, may improve survival without progress (PFS);

· Polymeric adenosine diphosphate ribose polymerase (PARP) inhibitor refractory breast cancer shows a certain effect, subject to the third stage of clinical studies.

Early breast cancer

For 2009, the United States society of Clinical Oncology (ASCO) annual meeting in early breast cancer study collection, the Academy of military medical sciences affiliated hospital (PLA 307 hospital) jiangze flew Professor organizations discussed scholars.

For Professor Jiang's how to treat this year, ASCO's annual meeting for T1 ~ 2N0 ~ 1 period of research findings in patients with breast cancer, the Chinese Academy of Medical Sciences Professor Yu zihao's Cancer Hospital, currently on T1 ~ 2N0 ~ 1 mastectomy patients with breast cancer and adjuvant chemotherapy is given after the controversial radiotherapy. As noted by the researchers, the research methodology exists two obvious defects, first of all, this is a retrospective study, followed two groups of patients in treatment is not completely consistent, will receive mastectomy patients and patients with breast-conserving therapy accepted for comparison is not always appropriate, therefore we have carefully results for this study. Some of the ongoing research may be able to give answers to this problem.

Guangdong provincial people's Hospital, the Guangdong provincial Lung Cancer Institute Professor Wu a dragon of radiotherapy for breast cancer patients with long-term effects, Professor Yu zihao's introduction, radiotherapy long-term follow-up has been more concerned about the problem. Before you consider breast cancer radiation therapy is the major complications of cardiac toxicity, but now with the irradiation technology standards, long-term follow-up results of radiation therapy for cardiac toxicity did not increase significantly, so if you can strictly control the indications and guarantee the quality of radiation technology, radiation therapy should not be cause long-term effects in patients with breast cancer.

Advanced breast cancer and breast cancer drug

For advanced breast cancer and breast cancer research, new selection of United States Washington Cancer Institute Swain (Swain) are summarized.

Advanced breast cancer treatment is mainly based on the biology of cancer, estrogen receptor (ER) and/or progesterone receptor (PR) positive people may choose hormone therapy; for ER and (or) PR-negative or endocrine treatment of tolerance, if human epidermal growth factor receptor 2 (HER2) overexpression, chemotherapy and Trastuzumab treatment of HER2 expression, if negative, you can choose to chemotherapy.

Although the combined with chemotherapy in remission rate and overall survival (OS) has certain advantages, but greater toxicity. Therefore, unless it is in urgent need to reduce tumor load conditions, generally it is recommended to select a single-drug therapy. But clinical or should be based on the biology of cancer, treatment, patients will, tumor load, and so on comprehensive measure to determine the choice of treatment. AVADO study E2100 and have confirmed that bevacizumab combined with taxane first-line therapy in MBC improves PFS, ASCO Annual meeting this year RIBBON-1 studies show that bevacizumab combined with anthracyclines, Capecitabine chemotherapy also may extend PFS period, but no significant differences in the OS.

PARP inhibitor selectivity killer BRCA1/2 gene defect cell. In addition, the gene expression profile displays, in a majority of three-negative breast cancer (ER, PR and HER2 are negative, TNBC) significant increases in PARP1 patients. This year, ASCO's annual meeting of the two phase II study results confirmed that the PARP inhibitor BSI-201 and olaparib for three negative breast cancer and BRCA mutations in breast cancer encouraging, but the second stage of the results is not sufficient to conclude that the best treatment option for precise conclusions, should be treated with caution.

(Liao Lily)

Some featured research

· A study shows that the United States, for example T1 «4240 2N0 ~ 1-stage breast cancer, mastectomy no postoperative radiation therapy to the distant metastasis risk significantly higher than the portion after postoperative radiation therapy (HR = 1.38, P = 0.002).

(Report Yu zihao 's)

· RIBBON-1 research shows that for 1237 cases have not previously received treatment for metastatic breast cancer patients, Capecitabine or taxanes/anthracycline joint bevacizumab can significantly extend PFS period (the researchers assessed 8.6 months pair 5.7 months; 9.2 months pair 8.0 months), but the OS was not significantly improved.

(The speaker jiangze fly)

· A phase II study of Gemcitabine + carboplatin chemotherapy in BSI-201 can significantly extend the OS issue (9.2 months pair 5.7 months); another study shows at stage, olaparib (400 mg, twice daily oral) treatment of BRCA mutations in patients with advanced breast cancer in remission rate of 41%, PFS 5.7 months period.

(Fudan University Cancer Hospital reported person Hu XI Chun)

(Editors: Deng 1m1m Yihong)